Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime

Status Enrolling by invitation

Clinical Trial Summary

Fluorescent lifetime microscopy has emerged as a useful tool to study fluorescent lifetimes in vitro. Fluorescence lifetime represents the average amount of time a fluorophore remains in the excited state following excitation and depends on the fluorophores molecular environment. Fluorescence lifetime ophthalmoscopy (FLIO) is a technique which can quantify fluorescence lifetimes in the human retina in vivo. The purpose of this study is to investigate fluorescence lifetime characteristics in the human retina by using a FLIO. The investigators hypothesize that FLIO will allow to identify areas of retinal metabolic stress such as ischemia by detecting changes in fluorescence lifetimes.

Clinical Trial Description

Background Ophthalmic imaging has made considerable progress in the last years. Especially the introduction of optical coherence tomography and the scanning laser ophthalmoscope has helped to understand the structural changes underlying various retinal diseases. However, the appearance of structural changes during retinal disease often represents irreversible functional loss with only limited treatment options. In order to prevent loss of vision, retinal diseases should ideally be diagnosed before structural changes occur. This can be achieved by imaging metabolic changes of the retina as most retinal diseases such as age related macular degeneration or diabetic retinopathy are associated with distinct metabolic changes, mainly related to oxidative stress. Recently, a novel device for imaging fluorescent lifetimes of the retina in vivo, the fluorescent lifetime ophthalmoscope (FLIO), has been developed. This device is able to measure fluorescence lifetimes in the retina on a macroscopic level and may be able to shed new light on metabolic diseases of the retina. Objective To define fluorescence lifetime characteristics in healthy patients and patients with various retinal diseases. Methods The investigators will use a novel device, the fluorescence lifetime ophthalmoscope (FLIO) to investigate fluorescence lifetimes in the human retina. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01981148
Study type	Observational
Source	University Hospital Inselspital, Berne
Contact
Status	Enrolling by invitation
Phase
Start date	February 2013
Completion date	May 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02972853` - Mindful Self-Regulation fMRI Pilot Study	N/A
Completed	`NCT02879565` - Families Expectations and Hope Raised by an Evaluation of Consciousness in Patients in a Vegetative State	N/A
Recruiting	`NCT03893006` - Vehicle Automation Impact on Drivers	N/A
Active, not recruiting	`NCT02826733` - Evaluation of the Implementation of the Hemispheric Dominance During Development
Completed	`NCT03531580` - Comparing Brain Images Before and After MRI-upgrade - TimFit Upgrade Study	N/A
Completed	`NCT02959489` - Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)	N/A
Completed	`NCT03313674` - Investigation of Seasonal Variations of Brain Structure and Connectivity in SAD	N/A
Recruiting	`NCT05776602` - Fast Brain MRI in Children With Suspected Brain Tumor
Completed	`NCT05262790` - The Difference of Grey Matter Volume Among the Patients of Schizophrenia
Completed	`NCT03501004` - The Study of Acupuncture on Vascular and Functional Neuroimaging in Parkinson's Disease Patients With Sleep Disorders	N/A
Recruiting	`NCT05698511` - Neural and Physiological Correlates of Psychedelic Sub-states	Phase 1
Not yet recruiting	`NCT03591315` - Clinical Study of Structural and Functional Evaluation of the Visual Pathway
Recruiting	`NCT04951700` - Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
Withdrawn	`NCT04671836` - Lorazepam Effects on Neuroimaging Measures	Early Phase 1
Not yet recruiting	`NCT05140850` - Long-term Consequences of Neuroimaging and Perceived Cognitive Dysfunction in oPRES
Completed	`NCT01514630` - Creatine as a Treatment Option for Depression in Methamphetamine Using Females	Phase 4
Completed	`NCT02939885` - fMRI Study of Brain Mechanisms Related to Emotions	N/A
Recruiting	`NCT04696315` - Early Diagnosis of SCD Based on Radiogenomics
Completed	`NCT03475823` - Cognitive and Blood Flow Effects of Mountain Tea	N/A
Completed	`NCT04135105` - Lexical Tone Perception in Tone language--a fMRI Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope — FLIO-Group

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms